VDR-Mediated Ferroptosis Drives Salivary Hyposecretion in Sod1 Knockout Female Mice

Study Background and Research Question

Salivary gland dysfunction, manifesting as xerostomia (dry mouth), affects a significant proportion of the aging population, with women disproportionately impacted. While oxidative stress has long been linked to reduced salivary flow and glandular damage, the molecular mechanisms underlying this association, particularly regarding sex differences, remain unclear. The reference study by Han et al. (2025) addresses this knowledge gap by exploring whether ferroptosis—a regulated form of cell death characterized by iron-dependent lipid peroxidation—contributes to salivary hyposecretion in a superoxide dismutase 1 gene (Sod1) knockout (SKO) mouse model, and how vitamin D receptor (VDR) upregulation might modulate this process (Han et al., 2025).

Key Innovation from the Reference Study

The innovation of Han et al.'s work lies in establishing a mechanistic link between VDR upregulation and ferroptosis-mediated loss of salivary gland function under oxidative stress. While previous studies have described the broad role of oxidative stress in glandular dysfunction, this research is among the first to demonstrate that VDR directly promotes ferroptosis in salivary tissues, particularly in females, by upregulating the transferrin receptor (TFRC), thereby linking hormonal regulation, oxidative injury, and cell death pathways in the etiology of xerostomia (Han et al., 2025).

Methods and Experimental Design Insights

Han et al. utilized a combination of in vivo and in vitro approaches:

• Animal Model: Female and male Sod1 knockout (SKO) mice were used to model chronic endogenous oxidative stress. This model is characterized by elevated reactive oxygen species (ROS) and increased lipid peroxidation, closely mimicking the redox imbalance seen in human aging and disease states [paper|DOI].
• Salivary Secretion Measurement: Stimulated salivary flow rates were quantified in both sexes, revealing marked reduction only in female SKO mice [paper|DOI].
• Molecular Profiling: RNA sequencing and qPCR analyses of submandibular glands identified altered gene expression signatures related to ferroptosis, inflammation, and circadian rhythm, with VDR and TFRC among the most significantly upregulated in affected female mice [paper|DOI].
• Cellular Model: Human A253 salivary gland epithelial cells were exposed to 4-nitroquinoline N-oxide (4NQO) to induce superoxide-driven oxidative stress. In these cells, VDR overexpression experiments confirmed direct transcriptional activation of the TFRC promoter, leading to enhanced susceptibility to ferroptosis [paper|DOI].

Core Findings and Why They Matter

The authors report several key findings:

• Female SKO mice, but not males, showed a significant decrease in salivary secretion correlated with elevated ROS, VDR expression, and ferroptosis pathway activation [paper|DOI].
• Histological analyses revealed increased cell death with morphological and molecular hallmarks of ferroptosis in the submandibular glands of female SKO mice, including upregulation of TFRC and other ferroptosis-related genes [paper|DOI].
• In vitro, VDR overexpression in A253 cells promoted TFRC expression and increased susceptibility to ferroptosis under oxidative stress, providing evidence of a direct mechanistic pathway [paper|DOI].

These results collectively suggest that VDR is a critical modulator of iron metabolism and ferroptotic cell death in salivary gland epithelium under oxidative stress, and that targeting the VDR–TFRC axis may represent a novel therapeutic strategy for the prevention or treatment of dry mouth conditions, especially in postmenopausal women or other high-risk groups.

Comparison with Existing Internal Articles

Recent internal resources provide practical context for the reference study’s mechanistic findings:

• The article "Liproxstatin-1: Advanced Insights into Ferroptosis Inhibition" expands on the molecular mechanisms by which ferroptosis inhibitors like Liproxstatin-1 disrupt iron-dependent cell death, supporting the translational relevance of targeting ferroptosis in organ dysfunction.
• "Liproxstatin-1: Potent Ferroptosis Inhibitor for Advanced Ferroptosis Research" details the compound’s robust inhibition of lipid peroxidation and selective cytoprotection in GPX4-deficient models, paralleling the reference study’s focus on lipid peroxidation and ferroptosis in glandular tissue.
• "Optimizing Ferroptosis Assays: Scenario Solutions with Liproxstatin-1" provides workflow recommendations for assay optimization and endpoint interpretation, which can be adapted to studies of salivary gland ferroptosis.

By synthesizing these sources, researchers can better design experiments that assess the inhibition of lipid peroxidation and ferroptosis in exocrine tissues, using validated ferroptosis inhibitors as positive controls or rescue agents.

Protocol Parameters

• assay: Lipid peroxidation measurement (BODIPY 581/591 C11 oxidation) | value_with_unit: n/a (fluorescence ratio) | applicability: Detection of ferroptotic lipid peroxidation in glandular or epithelial tissues | rationale: Direct quantification of lipid ROS, a ferroptosis hallmark | source_type: paper [DOI]
• assay: Ferroptosis inhibitor (Liproxstatin-1) positive control | value_with_unit: 22 nM (IC50) in GPX4-deficient cells | applicability: Benchmark for inhibition of lipid peroxidation and ferroptotic cell death | rationale: Defines sensitivity and rescue efficacy in ferroptosis assays | source_type: product_spec [APExBIO]
• assay: VDR overexpression | value_with_unit: Transient plasmid transfection (μg/ml, cell line-dependent) | applicability: Functional testing of transcriptional regulation of ferroptosis genes | rationale: Confirms direct impact of VDR on TFRC promoter activity | source_type: paper [DOI]
• assay: Ferroptosis induction (4NQO, erastin, RSL3) | value_with_unit: μM range (compound-specific) | applicability: Induction of ferroptosis for mechanistic studies | rationale: Standardize stress conditions to benchmark rescue by inhibitors | source_type: workflow_recommendation [internal_article]

Limitations and Transferability

While Han et al.'s findings provide compelling evidence that VDR-driven ferroptosis underlies sex-specific salivary hyposecretion in a Sod1 knockout model, several limitations warrant consideration:

• The study focuses on genetic knockout and overexpression systems, which may not fully recapitulate the multifactorial nature of human xerostomia.
• Findings are specific to female mice and may not directly translate to males or to humans without further validation.
• Pharmacological inhibition of ferroptosis (e.g., using Liproxstatin-1) was not tested in vivo in this model, leaving open questions about therapeutic efficacy in the context of salivary gland dysfunction.

Nevertheless, the demonstration that VDR upregulation increases ferroptosis susceptibility provides a strong rationale for testing ferroptosis inhibitors in future preclinical or translational studies of glandular hypofunction.

Research Support Resources

To facilitate studies of ferroptosis in salivary and other exocrine tissues, researchers may utilize validated chemical tools. Liproxstatin-1 (SKU B4987) is a potent ferroptosis inhibitor with an IC50 of 22 nM in GPX4-deficient models, and is widely used to benchmark the inhibition of lipid peroxidation and to evaluate protection against ferroptotic cell death [product_spec|APExBIO]. For protocol selection, scenario-driven guidance is available in internal articles such as "Optimizing Ferroptosis Assays: Scenario Solutions with Liproxstatin-1" and "Liproxstatin-1: Potent Ferroptosis Inhibitor for Advanced Ferroptosis Research." These resources support rigorous assay design and interpretation in ferroptosis research, including models of GPX4 deficiency and tissue injury.